Director of the Institute<br />for Cell Gene and Immunotherapies<br />University of Minnesota<br />USA
Prof. John Wagner, MD
Topic: Engineered Regulatory T cells to Enhance GVHD-free, Relapse-free survival after Allogeneic Hematopoietic Stem Cell Transplantation
John E Wagner, MD, is a Professor in the Division of Transplant and Cell Therapy in the Department of Pediatrics. He is also the McKnight-Presidential Endowed Chair, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy. He received his MD at Jefferson Medical College in Philadelphia, completed his residency at Duke University Medical School and post-doctoral fellowship at The Johns Hopkins University School of Medicine where he focused his clinical and research efforts in hematopoietic stem cell transplantation and graft engineering. Dr. Wagner’s primary research is focused on the development of novel cellular therapies to reduce the risks of graft failure, prolonged immune deficiency and relapse in recipients of blood and marrow transplantation and relapsed/refractory leukemia. He is the principal investigator of a recently renewed NCI-sponsored program project grant currently in its 26th year (as of 5/2023) supporting work on the development of engineered off-the-shelf allogeneic cancer immune effector cell therapies. In addition, he co-leads the Fanconi Anemia Comprehensive Care Center focused on the development of safer strategies for the treatment of marrow failure and cancer common to FA patients with this DNA-repair disorder. Dr. Wagner is the co-Director of Transplant and Cell Therapies Program at the University of Minnesota Masonic Cancer Center as well as the co-Leader of the Translational Therapies Laboratory Core.